Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab

Journal for ImmunoTherapy of Cancer

Tibor Keler²  Henry C. Marsh³  Max Bylesjo¹  Biwei Zhao²  Karuna Sundarapandiyan²  Venky Ramakrishna² 

[1] FiosGenomics, Edinburgh EH16 4UX, UK;Celldex Therapeutics, Inc., Hampton 08827, NJ, USA;Celldex Therapeutics, Inc., Needham 02494, MA, USA

关键词: Monoclonal antibody;    T cells;    Immunotherapy;    CD27;    Costimulation;   

Others  :  1225063
DOI  :  10.1186/s40425-015-0080-2

 received in 2015-03-17, accepted in 2015-07-03,  发布年份 2015

【 摘 要 】

Background

Clinical targeting of TNFR family of receptors (CD40, CD134 and CD137) with immunostimulatory monoclonal antibodies has been successful in cancer immunotherapy. However, targeting of CD27 with a mAb is a relatively new approach to provide costimulation of immune cells undergoing activation. Thus, activation of human CD27 (TNFRSF7) with a monoclonal antibody (varlilumab) has previously been demonstrated to result in T cell activation and anti-tumor activity in preclinical models, and is currently in early phase clinical trials in patients with advanced malignancies. In this study we used an in vitro system using human peripheral blood T cells to characterize the varlilumab-mediated costimulatory effects in combination with TCR stimulation in terms of phenotypic, transcriptional and functionality changes.

Methods

T cells were isolated from normal volunteer PBMCs using magnetic bead isolation kits and stimulated in vitro with plate bound anti-CD3 Ab (OKT3) and varlilumab or control Ab for 72 h. Activation profiles were monitored by ELISA or Luminex-based testing cytokine/chemokine releases, cell surface phenotyping for costimulatory and coinhibitory markers and CFSE dye dilution by proliferating T cells and Tregs. Changes in gene expression and transcriptome analysis of varlilumab-stimulated T cells was carried on Agilent Human whole genome microarray datasets using a suite of statistical and bioinformatic software tools.

Results

Costimulation of T cells with varlilumab required continuous TCR signaling as pre-activated T cells were unable to produce cytokines with CD27 signaling alone. Analysis of T cell subsets further revealed that memory CD4+ and CD8+ T cells were specifically activated with a bias toward CD8+ T lymphocyte proliferation. Activation was accompanied by upregulated cell surface expression of costimulatory [4-1BB, OX40, GITR and ICOS] and coinhibitory [PD-1] molecules. Importantly, varlilumab costimulation did not activate purified Tregs as measured by cytokine production, proliferation and suppression of dividing non-Treg T cells. Analysis of changes in gene expression during varlilumab stimulation of T cells revealed modulation of pro-inflammatory signatures consistent with cellular activation and proliferation, with the IL-2 pathway showing the highest frequency of gene modulation.

Conclusions

Altogether, the data reveal the requirements and T cell subtype-specific effects of CD27 costimulation, and helps select relevant biomarkers for studying the effects of varlilumab in patients.

【 授权许可】

   
2015 Ramakrishna et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Fig. 5.

Fig. 6.

【 参考文献 】

• [1]Hintzen RQ, de Jong R, Lens SM, Brouwer M, Baars P, van Lier RAW. Regulation of CD27 expression on subsets of mature T-lymphocytes. J Immunol. 1993; 151:2426-2435.
• [2]Bowman MR, Crimmins MA, Yetz-Aldape J, Kriz R, Kelleher K, Herrmann S. The cloning of CD70 and its identification as the ligand for CD27. J Immunol. 1994; 152:1756-1761.
• [3]Tesselaar K, Xiao Y, Arens R, van Schijndel GMW, Schuurhuis DH, Mebius RE et al.. Expression of the murine CD27 ligand CD70 in vitro and in vivo. J Immunol. 2003; 170:33-40.
• [4]Hintzen RQ, Lens SM, Beckmann MP, Goodwin RG, Lynch D, van Lier RA. Characterization of the human CD27 ligand, a novel member of the TNF gene family. J Immunol. 1994; 152:1762-1773.
• [5]Hintzen RQ, Lens SM, Lammers K, Kuiper H, Beckmann MP, van Lier RA. Engagement of CD27 with its ligand CD70 provides a second signal for T cell activation. J Immunol. 1995; 154:2612-2623.
• [6]Kobata T, Agematsu K, Kameoka J, Schlossman SF, Morimoto C. CD27 is a signal-transducing molecule involved in CD45RA+ naïve T cell costimulation. J Immunol. 1994; 153:5422-5432.
• [7]Hendriks J, Gravestein LA, Tesselaar K, van Lier RAW, Schumacher TNM, Borst J. CD27 is required for generation and long-term maintenance of T cell immunity. Nat Immunol. 2000; 1:433-440.
• [8]Hendriks J, Xiao Y, Borst J. CD27 promotes survival of activated T cells and complements CD28 in generation and establishment of the effector T cell pool. J Exp Med. 2003; 198:1369-1380.
• [9]Denoeud J, Moser M. Role of CD27/CD70 pathway of activation in immunity and tolerance. J Leukoc Biol. 2011; 89:1-9.
• [10]Song D-G, Ye Q, Poussin M, Harms GM, Figini M, Powell DJ. CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. Blood. 2012; 119(3):696-706.
• [11]Chen L, Flies DB. Molecular mechanisms of T cell costimulation and coinhibition. Nat Rev Immunol. 2013; 13:227-242.
• [12]Yao S, Zhu Y, Chen L. Advances in targeting cell surface signaling molecules for immune modulation. Nat Rev Drug Disc. 2013; 12:130-146.
• [13]Croft M. Costimulation of T cells by OX40, 4-1BB and CD27. Cytokine Growth Factor Rev. 2003; 14:265-273.
• [14]Kober J, Leitner J, Klauser C, Woitek R, Majdic O, Stockl J et al.. The capacity of the TNF family members 4-1BBL, OX40L, CD70, GITRL, CD30L and LIGHT to costimulate human T cells. Eur J Immunol. 2008; 38(10):2678-2688.
• [15]French RR, Chan HT, Tutt AL, Glennie MJ. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med. 1999; 5:548-553.
• [16]Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellström KE et al.. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med. 1997; 3:682-685.
• [17]Jensen SM, Maston LD, Gough MJ, Ruby CE, Redmond WL, Crittenden M et al.. Signaling through OX40 enhances antitumor immunity. Semin Oncol. 2010; 37(5):524-32.
• [18]Cohen AD, Schaer DA, Liu C, Li Y, Hirschhorn-Cymmerman D, Kim SC et al.. Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PLoS ONE. 2010; 5(5):e10436.
• [19]Vonderheide RH, Glennie MJ. Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res. 2013; 19:1035-1043.
• [20]Yonezawa A, Dutt S, Chester C, Kim J, Kohrt HE. Boosting cancer immunotherapy with anti-CD137 antibody therapy. Clin Can Res. 2015. [Epub ahead of print].
• [21]Curti BD, Kovacsovics-Bankowski M, Morris N, Walker E, Chisholm L, Floyd K et al.. OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res. 2013; 73:7189-98.
• [22]Arens R, Schepers K, Nolte MA, van Osterwijk ME, van Lier RAW, Schumaker TNM et al.. Tumor rejection induced by CD70-mediated quantitative and qualitative effects on effector CD8+ T cell formation. J Exp Med. 2004; 199:1595-1605.
• [23]French RR, Taraban VY, Crowther GR, Rowley TF, Gray JC, Johnson PW et al.. Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation. Blood. 2007; 109:4810-4815.
• [24]Sakanishi T, Yagita H. Anti-tumor effects of depleting and non-depleting anti-CD27 monoclonal antibodies in immune-competent mice. Biochem Biophys Res Commun. 2010; 393:829-835.
• [25]Roberts DJ, Franklin NA, Kingeter LM, Yagita H, Tutt AL, Glennie MJ et al.. Control of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8+ T cells. J Immunother. 2010; 33:769-779.
• [26]Vitale L, He L-Z, Thomas LJ, Widger J, Weidlick J, Crocker A et al.. Development of a human monoclonal antibody for potential therapy of CD27-expressing lymphoma and leukemia. Clin Cancer Res. 2012; 18(14):3812-3821.
• [27]He L-Z, Prostak N, Thomas LJ, Vitale L, Weidlick J, Crocker A et al.. Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice. J Immunol. 2013; 191:4174-4183.
• [28]Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array based on bias and variance. Bioinformatics. 2003; 19:185-193.
• [29]Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004; 3:Article 3.
• [30]Benjaminin Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc Ser B. 1995; 57:289-300.
• [31]Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N et al.. TM4: a free, open-source system for microarray data management and analysis. Biotechniques. 2003; 34(2):374-378.
• [32]Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011; 480:480-89.
• [33]Suntharalingham G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD et al.. Cytokine storm in a phase I trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006; 355:1018-1028.
• [34]Wischhusen J, Jung G, Radovanovic I, Beier C, Steinbach JP, Rimner A et al.. Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma. Cancer Res. 2002; 62:2592-2599.
• [35]Chahlavi A, Rayman P, Richmond AL, Biswas K, Zhang R, Vogelbaum M et al.. Glioblastomas induce T-lymphocyte death by two distinct pathways involving gangliosides and CD70. Cancer Res. 2005; 65:5428-38.
• [36]Aulwurm S, Wischhusen J, Friese M, Borst J, Weller M. Immune stimulatory effects of CD70 override CD70-mediated immune cell apoptosis in rodent glioma models and confer long-lasting antiglioma immunity in vivo. Int J Cancer. 2006; 118(7):1728-35.
• [37]Claus C, Reither C, Schurch C, Matter MS, Hilmenyuk T, Ochsenbein AF. CD27 signaling increases the frequency of regulatory T cells and promotes tumor growth. Cancer Res. 2012; 72(14):3364-3376.
• [38]Shin SM, Kim YH, Choi BK, Kwon PM, Lee H-W, Kwon BS. 4-1BB triggers IL-13 production from T cells to limit the polarized, Th1-mediated inflammation. J Leukoc Biol. 2007; 81:1455-1465.
• [39]Yamamoto H, Kishimoto T, Minamoto S. NF-κB activation in CD27 signaling: Involvement of TNF receptor-associated factors in its signaling and identification of functional region of CD27. J Immunol. 1998; 161:4753-4579.
• [40]Dumont FJ, Staruch MJ, Fischer P, DaSilva C, Camacho R. Inhibition of T cell activation by pharmacologic disruption of the MEK/ERK MAP kinase or calcineurin signaling pathways results in differential modulation of cytokine production. J Immunol. 1998; 160:2579-2589.
• [41]Peperzak V, Xiao Y, Veraar EAM, Borst J. CD27 sustains survival of CTLs in vrus-infected nonlymphoid tissue in mice by inducing autocrine IL-2 production. J Clin Invest. 2010; 120:168-178.
• [42]Duggleby RC, Shawn TN, Jarvis LB, Kaur G, Gaston JS. CD27 expression discriminates between regulatory and non-regulatory cells after expansion of human peripheral blood CD4+CD25+ cells. Immunology. 2007; 121:129-139.
• [43]Coquet JM, Ribot JC, Babala N, Middendorp S, van der Horst G, Xiao Y et al.. Epithelial and dendritic cells in the thymic medulla promote CD4+FoxP3+ regulatory T cell development via CD27-CD70 pathway. J Exp Med. 2013; 210:715-728.
• [44]Wakamatsu E, Mathis D, Benoist C. Convergent and divergent effects of costimulatory molecules in conventional and regulatory CD4+ T cells. Proc Natl Acad Sci. 2013; 110(3):1023-1028.
• [45]Golovina TN, Mikheeva T, Suhoski MM, Aqui NA, Tai VC, Shan X et al.. CD28 costimulation is essential for human T regulatory expansion and function. J Immunol. 2008; 18:2855-2868.
• [46]Bullock T, McClintic H, Jeong S, Smith K, Olson W, Ramakrishna V, et al. Immune correlates of Varlilumab treated cancer patients are consistent with CD27 costimulatory activity. J ImmunotherCancer. 2014;2 Suppl 3:100.
• [47]Riether C, Schürch C, Ochsenbein AF. Modulating CD27 signaling to treat cancer. Oncoimmunology. 2012; 1:1604-1606.